73930-39-9

Basic information

• Product Name: 1-PHENYL-CYCLOPROPYLAMINE HYDROCHLORIDE
• Synonyms: 1-PHENYL-CYCLOPROPYLAMINE HYDROCHLORIDE;TIMTEC-BB SBB008643;1-Phenylcyclopropanamine Hydrochloride;Cyclopropanamine, 1-phenyl-, hydrochloride (1:1);1-Phenylcyclopropan-1-amine hydrochloride;1-Phenyl-cyclopropylamine hydroc;1-PhenylcyclopropylaMine HCl;1-PhenylcyclopropanaMine, HCl
• CAS NO: 73930-39-9
• Molecular Formula: C₉H₁₁N*ClH
• Molecular Weight: 169.65128
• Product Categories: Amines and Anilines;API intermediates
• Mol File: 73930-39-9.mol
• Article Data: 18

Chemical Properties

• Melting Point: 194.7-194.9 °C
• Boiling Point: 211.4 °C at 760 mmHg
• Flash Point: 85.5 °C
• Appearance: /
• Vapor Pressure: 0.183mmHg at 25°C
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 1-PHENYL-CYCLOPROPYLAMINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-PHENYL-CYCLOPROPYLAMINE HYDROCHLORIDE(73930-39-9)
• EPA Substance Registry System: 1-PHENYL-CYCLOPROPYLAMINE HYDROCHLORIDE(73930-39-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 73930-39-9(Hazardous Substances Data)

Usage

General Description

1-PHENYL-CYCLOPROPYLAMINE HYDROCHLORIDE, also known as PCPA, is a chemical compound that is commonly used in research settings to study the effects of serotonin on the central nervous system. It is a psychoactive drug that has been shown to disrupt serotonin function, making it a useful tool for studying the role of serotonin in various physiological and behavioral processes. PCPA works by inhibiting the production of serotonin, leading to its depletion in the brain and resulting in a range of effects including altered mood, appetite, and sleep patterns. Due to its potential for altering serotonin levels, PCPA is also being investigated for its potential as a treatment for certain psychiatric disorders such as depression and anxiety. However, it must be used with caution and under strict supervision due to its psychoactive properties.

InChI:InChI=1/C9H11N.ClH/c10-9(6-7-9)8-4-2-1-3-5-8;/h1-5H,6-7,10H2;1H

Upstream product

• 75-16-1 methylmagnesium bromide 
• 100-47-0 benzonitrile 
• 7647-01-0 hydrogenchloride 
• 6120-95-2 1-phenyl-1-cyclopropane carboxylic acid 
• 925-90-6 ethylmagnesium bromide 
• 41049-53-0 1-phenylcyclopropylamine 
• 63201-02-5 1-phenylcyclopropanecarbonyl chloride 

Downstream Products

• 1598426-03-9 ethyl 2-((1-phenylcyclopropyl)amino)pyrimidine-5-carboxylate 
• 1375465-91-0 N-hydroxy-2-((1-phenylcyclopropyl)amino)pyrimidine-5-carboxamide 
• 80463-28-1 N(1-phenylcyclopropyl)-benzamide 

Relevant articles and documents

Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation

Abstract: LSD1 is a lysine demethylase highly involved in initiation and development of cancer. To design highly effective covalent inhibitors, a strategy is to fill its large catalytic cleft by designing tranylcypromine (TCP) analogs decorated with long,

HDAC INHIBITORS, ALONE OR IN COMBINATION WITH BTK INHIBITORS, FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA

Disclosed are histone deacetylase (HDAC) inhibitors, or combinations comprising an HDAC inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of chronic lymphocytic leukemia in a subject in need thereof. Also provided herein are methods for treating chronic lymphocytic leukemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor, or a combination comprising an HDAC inhibitor and a BTK inhibitor. Other related methods are disclosed.

HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY

The invention relates to HDAC inhibitors for use in the treatment of diabetic peripheral neuropathy in a subject in need thereof. Also provided herein are methods for treating diabetic peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor.